# Amgen (AMGN) — Earnings

AMGN · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/amgn/earnings

## Most recent quarter

| Metric | Value |
| --- | --- |
| Fiscal period | Q2 2026 |
| Period end | Jun 30, 2026 |
| EPS actual | $6.29 |
| EPS estimate | $5.62 |
| EPS surprise | +11.97% |
| Revenue surprise | +6.66% |
| Revenue | $10.1B |
| Revenue estimate | $9.4B |
| Reported | Aug 4, 2026 |
| SEC filing | [View filing](https://www.sec.gov:443/Archives/edgar/data/318154/000031815426000126/amgn-20260630.htm) |
| Earnings call | [Transcript](http://o.thsi.cn/dc-d-stock-america.teleconference/8bf04959-d9cc-63ee-3a65-5cda8f0b3032.html) |

Amgen reported Q2 2026 results on August 4, 2026. Earnings per share came in at $6.29, ahead of the $5.62 estimate by 11.97%. Revenue was $10.1 billion, 6.66% above the $9.4 billion consensus. Compared with Q2 2025, EPS rose about 4.5% from $6.02 and revenue rose about 10% from $9.2 billion. EPS also rose from $5.15 in Q1 2026.

The longer record shows steady growth. Annual EPS rose every year in the table, from $17.69 in 2022 to $18.65 in 2023, $19.82 in 2024 and $21.85 in 2025. Revenue grew faster, about 40%, from $26.3 billion in 2022 to $36.8 billion in 2025. The first half of 2026 adds up to $11.44 per share, about 5% more than the same period a year earlier. Q2 2026 set the highs here for both EPS and revenue and was the first above $10 billion. Over the last 20 quarters, Amgen topped the EPS estimate 18 times. The two misses, in Q4 2022 and Q2 2024, were each under 0.3%.

Amgen reported Q3 results between October 30 and November 4 in each of the past five years. That points to late October or early November 2026 for the next report.

## Earnings history

| Fiscal period | Report date | EPS estimate | EPS actual | Surprise | Revenue estimate | Revenue actual |
| --- | --- | --- | --- | --- | --- | --- |
| Q2 2026 | Aug 4, 2026 | $5.62 | $6.29 | 11.97% | $9.4B | $10.1B |
| Q1 2026 | Apr 30, 2026 | $4.77 | $5.15 | 8.04% | $8.6B | $8.6B |
| Q4 2025 | Feb 3, 2026 | $4.73 | $5.29 | 11.74% | $9.5B | $9.9B |
| Q3 2025 | Nov 4, 2025 | $5.02 | $5.64 | 12.37% | $9.0B | $9.6B |
| Q2 2025 | Aug 5, 2025 | $5.28 | $6.02 | 13.98% | $8.9B | $9.2B |
| Q1 2025 | May 1, 2025 | $4.27 | $4.90 | 14.76% | $8.1B | $8.1B |
| Q4 2024 | Feb 4, 2025 | $5.09 | $5.31 | 4.31% | $8.9B | $9.1B |
| Q3 2024 | Oct 30, 2024 | $5.27 | $5.58 | 5.79% | $8.5B | $8.5B |
| Q2 2024 | Aug 6, 2024 | $4.98 | $4.97 | -0.29% | $8.4B | $8.4B |
| Q1 2024 | May 2, 2024 | $3.88 | $3.96 | 2.09% | $7.5B | $7.4B |
| Q4 2023 | Feb 6, 2024 | $4.59 | $4.71 | 2.58% | $8.1B | $8.2B |
| Q3 2023 | Oct 31, 2023 | $4.67 | $4.96 | 6.23% | $6.9B | $6.9B |
| Q2 2023 | Aug 3, 2023 | $4.49 | $5.00 | 11.29% | $6.7B | $7.0B |
| Q1 2023 | Apr 27, 2023 | $3.85 | $3.98 | 3.45% | $6.2B | $6.1B |
| Q4 2022 | Jan 31, 2023 | $4.10 | $4.09 | -0.17% | $6.7B | $6.8B |
| Q3 2022 | Nov 3, 2022 | $4.47 | $4.70 | 5.22% | $6.6B | $6.7B |
| Q2 2022 | Aug 4, 2022 | $4.43 | $4.65 | 4.90% | $6.5B | $6.6B |
| Q1 2022 | Apr 27, 2022 | $4.10 | $4.25 | 3.78% | $6.1B | $6.2B |
| Q4 2021 | Feb 7, 2022 | $4.04 | $4.36 | 8.04% | $6.9B | $6.8B |
| Q3 2021 | Nov 2, 2021 | $4.29 | $4.67 | 8.73% | $6.7B | $6.7B |

## Frequently Asked Questions

### When did Amgen (AMGN) last report earnings?

Amgen last reported on Aug 4, 2026, covering fiscal Q2 2026.

### Did AMGN beat earnings estimates?

Yes. Amgen reported EPS of $6.29 for Q2 2026 against a $5.62 estimate — a 11.97% beat.

### How much revenue did AMGN report last quarter?

Amgen reported $10.1B in revenue for Q2 2026, against a consensus estimate of $9.4B.

## Similar Stocks

- [ABBV](https://www.lighthorse.io/tickers/abbv) — AbbVie Inc. Common Stock
- [GILD](https://www.lighthorse.io/tickers/gild) — Gilead Sciences, Inc. - Common Stock
- [VRTX](https://www.lighthorse.io/tickers/vrtx) — Vertex Pharmaceuticals Incorporated - Common Stock
- [MRK](https://www.lighthorse.io/tickers/mrk) — Merck & Company, Inc. Common Stock (new)
- [AZN](https://www.lighthorse.io/tickers/azn) — AstraZeneca PLC Ordinary Shares
- [LLY](https://www.lighthorse.io/tickers/lly) — Eli Lilly and Company Common Stock
- [PFE](https://www.lighthorse.io/tickers/pfe) — Pfizer, Inc. Common Stock
- [BMY](https://www.lighthorse.io/tickers/bmy) — Bristol-Myers Squibb Company Common Stock
- [MRNA](https://www.lighthorse.io/tickers/mrna) — Moderna, Inc. - Common Stock
- [REGN](https://www.lighthorse.io/tickers/regn) — Regeneron Pharmaceuticals, Inc. - Common Stock

---

Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).